AQST News and Press, Aquestive Therapeutics Inc. From 03/20/24

2024-03-20 08:11:18 ET More on pre-market losers & stocks. Prudential: Consider Both Upcoming Results And 2024 Risk Factors Euronav NV: Not Backing Down On The Decarbonization Agenda Euronav NV 2023 Q4 - Results - Earnings Call Presentation Solidion Techn...

2024-03-20 05:27:04 ET More on related stocks: Intel: CEO Gelsinger Fulfilling The Goals While Reducing Uncertainty NuScale Power Corporation (SMR) Q3 2023 Earnings Call Transcript NuScale Power Corporation 2023 Q4 - Results - Earnings Call Presentation Aques...

2024-03-20 03:37:53 ET More on Aquestive Therapeutics Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1 Aquestive Therapeutics reports mixed Q4 results; initiates FY24 outlook Seeking Alpha’s Quant Rating on Aquestive Therapeut...

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...

2024-03-19 17:37:35 ET Gainers: Taysha Gene Therapies ( TSHA ) +32% . Canopy Growth Corporation ( CGC ) +14% . Sarcos Technology and Robotics ( STRC ) +12% . Adicet  ( ACET ) +6% . Bridger Aerospace Group Holdings ( BAER ) +4%...

2024-03-19 16:05:18 ET More on Aquestive Therapeutics Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game...

2024-03-18 18:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-14 18:32:04 ET DENVER, Colo., Mar 14, 2024 ( 247marketnews.com )- Aquestive Therapeutics, Inc. (NASDAQ: AQST ) released positive topline clinical data from its Phase 3 pivotal pharmacokinetic (PK) clinical study of Anaphylm (epinephrine), the Company’s first and only ...

Anaphylm meets all predefined primary and secondary pharmacokinetic endpoints Anaphylm time to maximum concentration (Tmax) is consistently faster than autoinjectors Anaphylm exposure levels (AUC) are comparable to autoinjectors for 30 minutes after dosing Anaphylm is we...

2024-03-06 10:11:05 ET Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Conference Call March 06, 2024, 08:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Offic...